No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ATYR aTyr Pharma
- 1.860
- +0.220+13.41%
Close Jul 22 16:00 ET
- 1.850
- -0.010-0.54%
Pre 08:26 ET
128.36MMarket Cap-2113P/E (TTM)
1.869High1.580Low897.47KVolume1.700Open1.640Pre Close1.54MTurnover1.34%Turnover RatioLossP/E (Static)69.01MShares2.15052wk High1.52P/B124.85MFloat Cap1.08052wk Low--Dividend TTM67.12MShs Float396.060Historical High--Div YieldTTM17.62%Amplitude1.080Historical Low1.714Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
ATyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
RBC Capital Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $16
Buy Rating Affirmed: ATyr Pharma's Positive Clinical Developments and Strategic Expansion
Express News | ATyr Pharma Completes Enrollment Of 268 Patients In Largest Ever Pulmonary Sarcoidosis Study; Topline Data Expected Q3 2025
ATyr Pharma Completes Enrollment Of 268 Patients, Exceeding Target Enrollment In Global Pivotal Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis
ATyr Pharma, Inc. (NASDAQ:ATYR) Is Largely Controlled by Institutional Shareholders Who Own 61% of the Company
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
